Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

6.740 +0.070 (+1.05%)

Streaming Delayed Price Updated: 10:42 AM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	92,938
Open	6.700
Bid (Size)	6.730 (500)
Ask (Size)	6.750 (300)
Prev. Close	6.670
Today's Range	6.580 - 6.750
52wk Range	1.730 - 11.41
Shares Outstanding	30,674,855
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

November 20, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Performance

YTD	+50.1%	+50.1%
1 Month	-26.3%	-26.3%
3 Month	-4.8%	-4.8%
6 Month	+100.6%	+100.6%
1 Year	+36.7%	+36.7%

More News

Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025

November 10, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗

October 24, 2025

Via Stocktwits

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

October 22, 2025

Via Benzinga

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

October 14, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

October 07, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination

October 01, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

September 24, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

September 17, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

September 10, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

August 26, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Tops Q2 EPS Forecast ↗

August 13, 2025

Via The Motley Fool

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 05, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

July 24, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

June 12, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 12, 2025

Via Benzinga

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 09, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

These stocks are moving in today's pre-market session ↗

June 04, 2025

Via Chartmill

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps ↗

June 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 04, 2025

Via Benzinga

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

June 04, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025

From Sagimet Biosciences Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?

Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.

What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?

Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?

The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market

What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?

The current price of Sagimet Biosciences Inc. - Series A Common Stock is 6.740

When was Sagimet Biosciences Inc. - Series A Common Stock last traded?

The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 11/24/25 10:42 AM ET

What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?

The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 206.75M

How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?

Sagimet Biosciences Inc. - Series A Common Stock has 207M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.